Literature DB >> 11358172

Comparison of the activity spectra against pathogens of bacterial strains producing a mutacin or a lantibiotic.

H Morency1, M Mota-Meira, G LaPointe, C Lacroix, M C Lavoie.   

Abstract

The increase of drug resistance among bacterial pathogens is currently a major threat in hospital settings. New and more efficient antibiotic compounds have to be developed to fight infectious diseases. In the present work, a deferred antagonism test was used to determine the activity of different bacterial strains producing either a mutacin or a lantibiotic against bacterial pathogens. The mutacins A, B, C, D, I, K, L, M, and nisins A and Z were active against all enterococci tested. Mutacins A and B, and nisins A and Z inhibited all the staphylococci tested. Except for the strains producing mutacins P, Q, and X, all the other producing strains inhibited the streptococci tested. Mutacins A, B, I, J, T, nisins A and Z, and epidermin inhibited the two antibiotic-resistant strains of Neisseria gonorrhoeae tested. Mutacins A, B, C, D, and nisins A and Z inhibited Campylobacter jejuni and Helicobacter pylori. Thus, the wide activity spectra of nisin A and Z are confirmed. These results also indicate that many of the mutacins, especially those of groups A, B, C, D, I, J, K, L, M, and T, could be candidates for further development as useful antibiotics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358172

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  14 in total

1.  Biology and genome sequence of Streptococcus mutans phage M102AD.

Authors:  Allan L Delisle; Ming Guo; Natalia I Chalmers; Gerard J Barcak; Geneviève M Rousseau; Sylvain Moineau
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

Review 2.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

3.  Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.

Authors:  Adam Pepperney; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06       Impact factor: 4.609

4.  Macedocin, a food-grade lantibiotic produced by Streptococcus macedonicus ACA-DC 198.

Authors:  Marina D Georgalaki; Erika Van Den Berghe; Dimitrios Kritikos; Bart Devreese; Jozef Van Beeumen; George Kalantzopoulos; Luc De Vuyst; Effie Tsakalidou
Journal:  Appl Environ Microbiol       Date:  2002-12       Impact factor: 4.792

Review 5.  The dual role of bacteriocins as anti- and probiotics.

Authors:  O Gillor; A Etzion; M A Riley
Journal:  Appl Microbiol Biotechnol       Date:  2008-10-14       Impact factor: 4.813

6.  Genetic Analysis of Mutacin B-Ny266, a Lantibiotic Active against Caries Pathogens.

Authors:  Delphine Dufour; Abdelahhad Barbour; Yuki Chan; Marcus Cheng; Taimoor Rahman; Matthew Thorburn; Cameron Stewart; Yoav Finer; Siew-Ging Gong; Céline M Lévesque
Journal:  J Bacteriol       Date:  2020-05-27       Impact factor: 3.490

7.  Capacity of human nisin- and pediocin-producing lactic Acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci.

Authors:  Mathieu Millette; Gilbert Cornut; Claude Dupont; François Shareck; Denis Archambault; Monique Lacroix
Journal:  Appl Environ Microbiol       Date:  2008-02-01       Impact factor: 4.792

Review 8.  Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

9.  Production, purification, sequencing and activity spectra of mutacins D-123.1 and F-59.1.

Authors:  Guillaume G Nicolas; Gisèle LaPointe; Marc C Lavoie
Journal:  BMC Microbiol       Date:  2011-04-10       Impact factor: 3.605

10.  Mutacin H-29B is identical to mutacin II (J-T8).

Authors:  Guillaume Nicolas; Hélène Morency; Gisèle LaPointe; Marc C Lavoie
Journal:  BMC Microbiol       Date:  2006-04-20       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.